Rislenemdaz

• Description :

  Rislenemdaz (CERC-301) is an orally bioavailable and selective N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B) antagonist with Ki and IC 50 of 8.1 nM and 3.6 nM, respectively.

• Product Name Alternative :

  MK-0657; CERC-301

• UNSPSC :

  12352005

• Target :

  IGluR

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/Rislenemdaz.html

• Purity :

  99.86

• Solubility :

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(N1C[C@@H](F)[C@@H](CNC2=NC=CC=N2)CC1)OCC3=CC=C(C)C=C3

• Molecular Formula :

  C19H23FN4O2

• Molecular Weight :

  358.41

• References & Citations :

  [1]Rachel Garner, et al. Preclinical pharmacology and pharmacokinetics of CERC‐301, a GluN2B‐selective N‐methyl‐D‐aspartate receptor antagonist. Pharmacol Res Perspect. 2015 Dec; 3 (6) : e00198.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  NMDA Receptor

• CAS Number :

  [808732-98-1]